Esperite (ESP), The Cell Factory demonstrate antiinflammatory mode of action of CF-MEV-117 extracellular vesicle drug candidate for Epilepsy

May 5, 2017 Group News

CF-MEV-117 drug development confirming an anti-inflammatory and immunosuppressive activity of the CF-MEV-117 in a dose response manner. Full results will be presented during the International Society for Extracellular Vesicles (ISEV) meeting in Toronto, Canada from 18-21 May, 2017.

Zutphen, The Netherlands – 5 May 2017

read more

Esperite N.V. (ESP) with CryoSave contributes to treating a 9 year old child with Thalassemia Major in Switzerland

April 25, 2017 Group News

CryoSave confirms the importance of cord blood stem cells in regenerative medicine.

Last week, CryoSave released a cord blood stem cell unit from the state of the art laboratory in Geneva for the clinical treatment of a young boy who suffers from thalassemia major. The 9 year old patient will receive an allogeneic transplant in Switzerland of the cord blood stem cells from his now 2 year old brother.

Zutphen, The Netherlands – 25 April 2017

read more

ESPERITE N.V. convenes Extraordinary General Meeting of Shareholders regarding external financing of up to EUR 13 million

March 10, 2017 Group News

Esperite N.V. (Euronext: ESP, “Esperite”) announces that it has convened an Extraordinary General Meeting of Shareholders (“EGM”) to be held on Friday 21 April 2017 at 14:00 hours CET at Hotel NH Amsterdam Barbizon Palace, Prins Hendrikkade, 59-72, 1012 AD, Amsterdam, The Netherlands.

Zutphen, The Netherlands – 10 March 2017

read more

Esperite secures external financing of up to EUR 9 million to support its commercial activity and development of innovative technologies

March 8, 2017 Financial Reports

Esperite secures external financing of up to EUR 9 million to support its commercial activity and development of innovative technologies

Total investment can reach EUR 13 million upon exercise of share subscription warrants

Zutphen, The Netherlands – 08 March 2017

read more

ESPERITE N.V.: Update on Financing

December 31, 2016 Group News

Esperite N.V. (Euronext: ESP, “Esperite” or “the Group”) announced during the year 2016 that it prepares a significant external funding to which the main shareholder will contribute along with potential other investors. The Group needs financial contribution to consolidate the existing business and accelerate its development for the benefit of its present and future shareholders.

Zutphen, The Netherlands – 31 December 2016

read more

Esperite N.V. (ESP) expands extracellular vesicles (exosomes) products portfolio to include inflammatory bowel disease.

October 20, 2016 Group News

The Cell Factory develops therapy for Crohn’s disease.

Esperite’s business unit The Cell Factory, in collaboration with Women’s and Children’s Health Department of the University of Padua and the Padua University Hospital have started a translational project on extracellular vesicles (including exosomes) first in man use in treatment of Crohn’s disease perianal fistulas. Inflammatory bowel disease (IBD) affects approximately 0.5% of the western countries population and this number is rapidly increasing. There are over 0.5 million people in the US and over 1 million in Europe with Crohn’s disease, with over 10 new cases per 100.000 people every year. The annual cost of therapy exceeds 5 billion USD in the US only (CDC). Up to 50% of Crohn’s disease patients are affected with difficult to treat perianal fistulas, and 75% require surgery (CDC).

Zutphen, The Netherlands – 20 October 2016

Page 10 of 46« First...89101112...203040...Last »